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Erlotinib and
Gastrointestinal Ulcer
To the Editor:
Erlotinib is an orally available epi-
dermal growth factor receptor-tyrosine
kinase inhibitor (EGFR-TKI) and has
been used as second- or third-line
treatment for non-small cell lung can-
cer worldwide.1 It is also approved for
pancreatic cancer in combination with
gemcitabine. Its toxicities are gener-
ally mild, with the major toxicities
being skin rash, diarrhea, and liver dys-
function. Recently, however, Genentech
and OSI Pharmaceuticals have issued im-
portant safety information, stating that pa-
tients receiving concomitant antiangio-
genic agents, corticosteroids, nonsteroidal
antiinflammatory drugs (NSAIDs), and/or
taxane-based chemotherapy, or who have
a history of peptic ulceration or diverticu-
lar disease are at greater risk for develop-
ing gastrointestinal perforation.2
Between March 2008 and March
2010, 103 patients with non-small cell
lung cancer were treated with erlotinib
in our hospital. All patients started erlo-
tinib as a single agent at a dose of 150
mg/body/d. We reviewed these patients
and identified five patients who devel-
oped gastrointestinal events during the
treatment period: four patients with hem-
orrhagic gastrointestinal ulcer confirmed
by gastrointestinal endoscopy and one pa-
tient with gastrointestinal perforation.
Table 1 shows the characteristics of all
103 patients. The significance of the rela-
tionships between clinical factors and the
onset of gastrointestinal events was eval-
uated using univariate analysis with
Fisher’s exact probability test. There
were no significant associations between
age, sex, performance status, history of
peptic ulcer, and the concomitant use of
steroids and anticoagulants and gastro-
intestinal events; however, only the use
of NSAIDs was significantly associated:
all five patients had received NSAIDs
concomitantly with erlotinib in the gas-
trointestinal event () group, whereas
29 of 98 patients had received NSAIDs
in the gastrointestinal event () group.
In addition, four of five patients had not
received either H2-blockers or proton-
pump inhibitors in the gastrointestinal
event () group, whereas 18 of 29 pa-
tients had not received in the gastroin-
testinal event () group. Only one pa-
tient had received H2-blocker in the
gastrointestinal event () group; how-
ever, he had also received steroids and
developed gastrointestinal perforation.
The incidence rate of 4.9% (5 of 103)
for gastrointestinal ulcer was fairly high,
although there is no conclusive proof
that all gastrointestinal events were
caused with erlotinib; however, consid-
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TABLE 1. Patient Characteristics
Gastrointestinal Event
() n  98
Gastrointestinal Event
() (n  5) p
Age (yr)
70 64 2 0.3472
70 34 3
Sex
Male 54 4 0.3831
Female 44 1
PS
0/1 72 2 0.1342
2/3/4 26 3
Histology
Ad 83 3 0.1898
Non-Ad 15 2
Prior history of peptic ulcer
Yes 7 0 0.9999
No 91 5
Use of NSAIDs
Yes 24 5 0.0014*
No 74 0
Use of steroids
Yes 18 1 0.9999
No 80 4
Use of H2-blockers
Yes 22 1 0.9999
No 76 4
Use of PPIs
Yes 5 0 0.9999
No 93 5
Use of anticoagulants
Yes 4 1 0.2242
No 94 4
PS, performance status; Ad, adenocarcinoma; NSAIDs, nonsteroidal antiinflammatory drugs; PPI, proton-
pump inhibitor. *, statistically significant.
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ering the brief time to the events from
the start of erlotinib (3, 3, 5, 21, and 58
days, respectively), it is highly probable.
Previous studies have shown that
EGFR was highly expressed in the epithe-
lium of the gastrointestinal tract, and se-
vere developmental disorders of the gas-
trointestinal epithelium were induced in
EGFR-knockout mice.3,4 Taking into ac-
count these preclinical data, our results
may not be so surprising.
In conclusion, erlotinib frequently
induces gastrointestinal ulcer when pa-
tients are administered NSAIDs without
antacids. Although antacids may weaken
the effectiveness of erlotinib by reducing
the blood concentration of erlotinib, on the
basis of our experiences, patients should
be given antacids to avoid gastrointestinal
ulcer when erlotinib and NSAIDs are ad-
ministered concomitantly.
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The Role of Surgery in
the Management of
Primary Thymic
Mucosa-associated
Lymphoid Tissue
(MALT) Lymphoma
To the Editor:
We read with great interest the
recent article in Journal of Thoracic
Oncology by Shimizu et al.,1 who pro-
posed a diagnosis flow chart (Figure 3)
for thymic mucosa-associated lymphoid
tissue (MALT) lymphoma. The diagno-
sis flow chart is creative and valuable
and presents a clear path of identifying
thymic MALT lymphoma. We extend
the topic by stressing the role of surgery
in the management of this rare disease.
As a malignant disease, thymic
MALT lymphoma must be diagnosed
finally by histologic examinations,
which are known as “golden standards.”
Given the extreme rarity of this disease,
some typical characteristics, as de-
scribed by Shimizu et al., may be im-
portant clues of thymic MALT lym-
phoma, but they are not yet “gold
standard” in diagnosis of this disease.
Thus, for exact histologic diagnosis, bi-
opsy is necessary. But in small biopsy,
such as percutaneous needle biopsy, it is
sometimes difficult to differentiate thymic
MALT lymphoma from thymoma be-
cause of similar histologic mixture of lym-
phoid cells and epithelial cells in small
biopsies.2 Then, surgery is usually un-
avoidable for enough tumor biopsy, as
reported in most cases of the literature.
On the other hand, according to
our experience and information from the
literature, thymic MALT lymphoma
seems to be a special lymphoma that
develops mostly within the thymus and
is often encapsulated by an intact mem-
brane.3 Local invasion or distal metasta-
sis is barely reported for this disease.
There should be no more difficulty to
perform a surgery on thymic MALT
lymphomas than on common thymomas.
Therefore, we suggest that when thymic
MALT lymphoma is highly suspected
by some typical characteristics, surgery
be reasonably recommended to manage
the anterior mediastinal mass. Surgery
should be performed not only as an
approach of obtaining enough tissues for
exact histologic diagnosis but also as a
choice of effective treatment by remov-
ing the disease completely.
Wei-An Song, MD
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In Response:
We thank Song and coworkers
for their letter in response to our recent
article on primary thymic mucosa-as-
sociated lymphoid tissue (MALT)
lymphoma published in the Journal of
Thoracic Oncology.1 We recommended
the diagnostic flow chart for a cystic
thymic mass but did not address the
role of surgery in the management of
this rare disease.
Song and coworkers stressed the
role of surgery in the management of
thymic MALT lymphoma. They sug-
gested that surgery should be per-
formed not only as an approach of
obtaining enough tissues for exact his-
tologic diagnosis but also as a choice
of effective treatment by removing the
disease completely. We fully agree
with their opinion. As has been re-
ported in the literature, thymic MALT
lymphoma is often encapsulated, and
local invasion or distal metastasis has
barely been reported.1,2 If completely
resected before it spreads, excellent
outcome is expected. However, if the
disease is left untreated and spreads
beyond encapsulation, its management
can be challenging.
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